Taiwan's ScinoPharm forges link for biosimilars production with US firm

Taiwan's ScinoPharm is to make an investment in the US firm Tanvex Biologics, with the intention of building up joint capacity for the manufacture of biosimilars in the US market.

Taiwan's ScinoPharm is to make an investment in the US firm Tanvex Biologics, with the intention of building up joint capacity for the manufacture of biosimilars in the US market.

The investment will take the form of assets, intellectual property and cash, and includes an equity stake in Tanvex. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Focus On Asia

Cipla Revs Up Biosimilars Engine Amid Winds Of Regulatory Change

 

Cipla’s partnered filgrastim biosimilar is expected to debut in the US in Q2 FY26 and the Indian firm expects an investment return ratio for its biosimilar engine “not too far” from that of a complex generic product amid an enabling regulatory environment.

With Planned US Facility Acquisition, Celltrion Looks To Avoid US Pharma Tariffs

 
• By 

Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

 

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.

GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.

More from Scrip

Merck & Co.’s Winrevair Growing Into The Revenue Driver Needed Post-Keytruda LOE

 
• By 

PAH drug Winrevair generated more than $1bn in sales in its first year on the US market, but the company plans to cut $3bn in costs through 2027 that it will reinvest in additional growth drivers.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Novo Selects Internal CEO To Recharge Growth

 

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.